Dr Travis Rieder discusses his own experiences with opioids and the ethical challenges of “legacy patients,” and Dr Stephanie Zaza, president of the American College of Preventive Medicine, discusses the future of opioid research priorities.
Produce prescription programs can expand patient's food choices and provide financial incentives to change consumption behaviors. If these programs are not linked to established government assistance programs, however, growers could be at risks for bearing the cost.
AMA J Ethics. 2018;20(10):E960-973. doi:
10.1001/amajethics.2018.960
Sociocultural and economic factors drive transition from plant-based to animal-based protein sources in rapidly developing and urbanizing countries of South Asia and Southeast Asia. Better understanding the health impact of this transition requires integrating epidemiological and social science research methods.
AMA J Ethics. 2018;20(10):E987-993. doi:
10.1001/amajethics.2018.987.
Claudia O. Gambrah-Sampaney, MD, Jesse E. Passman, MD, MPH, Andrielle Yost, MPA, and Glen N. Gaulton, PhD
In the past decade, more students than ever entered medical school with the desire, if not the expectation, of participating in meaningful global health experiences.
AMA J Ethics. 2019;21(9):E772-777. doi:
10.1001/amajethics.2019.772.
How would gathering preclinical data and improving research infrastructure facilitate clearer definitions of “population vulnerability” and “risk acceptability”?
AMA J Ethics. 2020;22(1):E43-49. doi:
10.1001/amajethics.2020.43.
Legacy patients are so-called because their opioid use behaviors express past, aggressive opioid prescribing by a clinician. Managing their pain and dependence justly is ethically complex.
AMA J Ethics. 2020;22(8):E651-657. doi:
10.1001/amajethics.2020.651.
A 3-step analgesic ladder was introduced in 1986 and needs change. Surgical interventions could reduce opioid use and motivate expansion of current pain management approaches.
AMA J Ethics. 2020;22(8):E695-701. doi:
10.1001/amajethics.2020.695.